Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 27, 2201-2206, November 1, 1967]
© 1967 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sartorelli, A. C.
Right arrow Articles by Creasey, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sartorelli, A. C.
Right arrow Articles by Creasey, W. A.

The Antineoplastic and Biochemical Effects of Some 5-Fluoropyrimidines1

Alan C. Sartorelli and William A. Creasey

Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06510

The comparative growth-inhibitory activities of 5-fluorouracil (5-FU), 4-hydroxy-5-fluoropyrimidine (4-HFP), and 2-hydroxy-5-fluoropyrimidine (2-HFP) were measured on Sarcoma 180 ascites cells. A marked extension of the life-span of tumor-bearing mice was afforded by i.p. injections of 5-FU, whereas both 4-HFP and 2-HFP were only weakly active. Sarcoma 180 ascites cells converted both 4-HFP and 5-FU into mono-, di-, and trinucleotide forms of 5-FU and incorporated the 5-fluoropyrimidines into RNA exclusively as 5-FU. Mice given i.p. injections of 4-HFP excreted the compound into the urine primarily as 5-FU and its metabolites. The incorporation of formate-14C into the thymine of DNA was inhibited by 5-FU, 4-HFP, and 2-HFP; measurement of the duration of inhibition by molar equivalent doses of these agents indicated that the longevity of blockade was greatest with 5-FU, while that caused by 2-HFP was the shortest. Administration of an inhibitor of the activity of xanthine oxidase, 4-hydroxypyrazolo(3,4-d)pyrimidine, reduced not only the slight tumor inhibition and toxicity produced by 4-HFP, but also the conversion of this agent to 5-FU and its metabolites and the degree of inhibition of the incorporation of formate-14C into DNA, suggesting that in order to manifest biologic and biochemical activity, 4-HFP must be converted to 5-FU. The incorporation of formate-14C and hypoxanthine-8-14C into the guanine of the nucleic acids was inhibited by 5-FU, whereas the utilization of these isotopic substrates for the formation of nucleic acid adenine was unaffected. The incorporation of guanine-8-14C into the guanine and adenine of the nucleic acid also was insensitive to the action of 5-FU, suggesting the presence of a 5-FU-sensitive site on the pathway from inosine 5'-phosphate to guanosine 5'-phosphate. The possible significance of these findings is discussed.

1 This research was supported by Grant CA-02817 from the National Cancer Institute, USPHS, and by Grant T-335B from the American Cancer Society. Presented in part at the 152nd Meeting of the American Chemical Society, New York, September, 1966.

Received 3/15/67. Accepted 7/12/67.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1967 by the American Association for Cancer Research.